AMPH Q1 2020 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q1 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$85M+6.1% YoY

Gross Profit

$37M43.5% margin

Operating Income

$7M8.8% margin

Net Income

$4M4.7% margin

EPS (Diluted)

$0.08

QoQ Revenue Growth

+1.6%

Cash Flow

Operating Cash Flow

$1M

Free Cash Flow

-$7M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$573M

Total Liabilities

$149M

Stockholders' Equity

$378M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$85M	$80M	+6.1%
Gross Profit	$37M	$31M	+19.2%
Operating Income	$7M	-$3M	+335.8%
Net Income	$4M	$868,000	+355.0%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$3M100%

Geographic Segments

U

$81M100%

C

$228,0000%